Companies · Biotechnology

SynGen Inc.

SACRAMENTO · Biotechnology

Diligence memoA one-page analyst read on SynGen Inc. — recommendation, valuation, rhythm, risks.
$15.2M
Total raised · real
13
Rounds
0.8×
Latest step-up
Top 37%
Sector rank · raised
Seed
Latest stage · inferred · Wed Jun 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

SynGen Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.25× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

SynGen Inc. is one of 4293 Biotechnology companies tracked from SACRAMENTO. By capital raised it ranks mid-pack (ahead of 64% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2012
Year incorporated
2017-06-14
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2012-04-17 Raised $2.0M (real) Modeled valuation $89M (est)Seed2012Seed · 2012-04-17 Raised $2.0M (real) Modeled valuation $89M (est)Seed2012Seed · 2013-07-02 Raised $1.0M (real) Modeled valuation $44M (est)Seed2013Seed · 2014-09-12 Raised $2.0M (real) Modeled valuation $89M (est)Seed2014Seed · 2015-03-25 Raised $2.3M (real) Modeled valuation $100M (est)Seed2015Seed · 2016-01-08 Raised $2.0M (real) Modeled valuation $89M (est)Seed2016Seed · 2016-04-26 Raised $1.6M (real) Modeled valuation $69M (est)Seed2016Seed · 2016-07-13 Raised $1.0M (real) Modeled valuation $44M (est)Seed2016Seed · 2016-11-14 Raised $1.0M (real) Modeled valuation $44M (est)Seed2016Seed · 2017-01-12 Raised $500K (real) Modeled valuation $22M (est)Seed2017Seed · 2017-02-21 Raised $500K (real) Modeled valuation $22M (est)Seed2017Seed · 2017-03-21 Raised $500K (real) Modeled valuation $22M (est)Seed2017Seed · 2017-04-18 Raised $500K (real) Modeled valuation $22M (est)Seed2017Seed · 2017-06-14 Raised $400K (real) Modeled valuation $18M (est)Seed2017Cumulative $17M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2012
Seed extension$2.0M · 2012
Seed extension$1.0M · 2013
Seed extension$2.0M · 2014
Seed extension$2.3M · 2015
Seed extension$2.0M · 2016
Seed extension$1.6M · 2016
Seed extension$1.0M · 2016
Seed extension$1.0M · 2016
Seed extension$500K · 2017
Seed extension$500K · 2017
Seed extension$500K · 2017
Seed extension$500K · 2017
Seed extension$400K · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$17.8M
Base estimate est.
$288K
Conservative case
$139.4M
Upside case
$2.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $88.8M · 2012-04-172012Seed · modeled $88.8M · 2012-04-17Seed · modeled $44.4M · 2013-07-02Seed · modeled $88.8M · 2014-09-12Seed · modeled $99.9M · 2015-03-25Seed · modeled $88.8M · 2016-01-08Seed · modeled $69.4M · 2016-04-26Seed · modeled $44.4M · 2016-07-13Seed · modeled $44.4M · 2016-11-14Seed · modeled $22.2M · 2017-01-12Seed · modeled $22.2M · 2017-02-21Seed · modeled $22.2M · 2017-03-21Seed · modeled $22.2M · 2017-04-18Seed · modeled $17.8M · 2017-06-142017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
9.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$2.9M/yr
Capital velocity
14.2 yr
On record since
2012
First round
14
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.1× above median
This company$15.2M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.2× of median
This company$400K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$17.8M
Sector median$64.2M

Raised more than 64% of sector peers (real $). Modeled value above 27% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #160 of 175.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)SynGen Inc. (this company) Raised $15.2M · modeled $17.8M (est)SynGen Inc.
CompanyStageRaised · realValue · estvs peer med.
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
Captozyme Inc.Seed$3.4M$151.0M2.12×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
SynGen Inc. this companySeed$15.2M$17.8M0.25×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2012-04-17$10.0M$88.8M85%
Seed$2.0M2012-04-17$10.0M$88.8M85%
Seed$1.0M2013-07-02$5.0M$44.4M85%
Seed$2.0M2014-09-12$10.0M$88.8M85%
Seed$2.3M2015-03-25$11.3M$99.9M85%
Seed$2.0M2016-01-08$10.0M$88.8M85%
Seed$1.6M2016-04-26$7.8M$69.4M85%
Seed$1.0M2016-07-13$5.0M$44.4M85%
Seed$1.0M2016-11-14$5.0M$44.4M90%
Seed$500K2017-01-12$2.5M$22.2M90%
Seed$500K2017-02-21$2.5M$22.2M90%
Seed$500K2017-03-21$2.5M$22.2M90%
Seed$500K2017-04-18$2.5M$22.2M90%
Seed$400K2017-06-14$2.0M$17.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2012-04-17
    • First recorded raise — entered as Seed.
    • 2 investors on this round.
  2. Seed$2.0M2012-04-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  3. Seed$1.0M2013-07-02
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • Switched to Rule 505 (was Rule 06).
    • 2 investors on this round.
  4. Seed$2.0M2014-09-12
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 505).
    • 2 investors on this round.
  5. Seed$2.3M2015-03-25
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  6. Seed$2.0M2016-01-08
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  7. Seed$1.6M2016-04-26
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 3 investors on this round.
  8. Seed$1.0M2016-07-13
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  9. Seed$1.0M2016-11-14
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 3 investors on this round.
  10. Seed$500K2017-01-12
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  11. Seed$500K2017-02-21
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  12. Seed$500K2017-03-21
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  13. Seed$500K2017-04-18
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  14. Seed$400K2017-06-14
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2017 ~Q4
Modeled next raise · ~5mo cadence
$400K
Modeled next size est.range $400K$640K
0.8×
Last step-up
$2.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Philip H. Coelho1 other2012-04
Carl A. Goldfischer2015-03
Chuck A. Novak2015-03
George H. Barry2012-04
Vic H. Schmitt2014-09
William H. Gerber2014-09
Woodrow A. Myers, Jr.2014-09
Registry & provenance

SynGen Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1547876
SEC CIK
2012
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Phaserx, Inc.BiotechnologySeed$16.1M$18.6Msame sector · same stage
Intelomed, Inc.BiotechnologySeed$13.4M$22.3Msame sector · same stage
Bio-Path Holdings IncBiotechnologySeed$19.9M$16.7Msame sector · same stage
Innovative Cardiovascular Solutions, LLCBiotechnologySeed$7.9M$13.0Msame sector · same stage
Biocurity Pharmaceuticals Inc.BiotechnologySeed$7.6M$13.3Msame sector · same stage
Tarpon Biosystems Inc.BiotechnologySeed$7.0M$13.1Msame sector · same stage
Virica Biotech Inc.BiotechnologySeed$7.0M$18.6Msame sector · same stage
e-Nicotine Technology, Inc.BiotechnologySeed$7.0M$17.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
SynLife, Inc.BiotechnologyPre-Seed$38.6M92%
Synlogic, Inc.BiotechnologySeries C$3.3B92%
Syndevrx IncBiotechnologySeries B$39.8M91%
Synlico Inc.BiotechnologySeed$10.1M91%
Syntis Bio, Inc.BiotechnologySeries B$118.0M90%
Syndex Bio Inc.BiotechnologySeries B$83.3M90%
Flugen IncBiotechnologySeries A$295.9M90%
Syntimmune, Inc.BiotechnologySeries B$714.4M89%
Frequently asked
How much funding has SynGen Inc. raised?
SynGen Inc. has raised approximately $15.2M in disclosed capital across 13 recorded financing rounds, aggregated from public filings.
What is SynGen Inc.'s estimated valuation?
Provath's modeled valuation for SynGen Inc. is approximately $17.8M (modeled range $288K–$139.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SynGen Inc. at?
SynGen Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Jun 14.
What does SynGen Inc. do and where is it based?
SynGen Inc. operates in the Biotechnology sector, based in SACRAMENTO.
Explore related

See where SynGen Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SynGen Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.